TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04621110
Drug: intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam will be administrated by intravenous route in 0,1mg/kg dose and the study will use this drug to compare the efficiency of intranasal drugs.
Study: NCT06122714
Drug: AZD4144 Part A
Normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: Participants will be administered a single oral dose on Day 1.
Study: NCT06122714
Drug: AZD4144 Part B
Normalized name: SODIUM CHLORITE 0.0256 kg in 1 kg TOPICAL SPRAY [Chlorsan 105 Part B]
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part B: Participants will be administered a single dose on Day 1, and repeated dosing will commence from Day 4 until Day 11 (inclusive) and a single dose on Day 12.
Study: NCT04105231
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol oral suspension
Study: NCT04105231
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone, encapsulated tablet.
Study: NCT05460325
Drug: Lanadelumab
Normalized name: Lanadelumab
DrugBank: Lanadelumab (DB14597)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lanadelumab subcutaneous injection
Study: NCT06670872
Drug: Eravacycline combination therapy group
DrugBank: AVAC (DB05441)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physicians determine the combination regimen of eravacycline, which may include sulbactam or compound preparations containing sulbactam, polymyxin B, beta-lactam antibiotics, etc., based on the pathogen identification and susceptibility results, and the China Guidelines for Diagnosis, Treatment, and Prevention of Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria. The combined drugs are used according to their instructions for use or clinical practice guidelines.
Study: NCT06246786
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will begin treatment at 5mg/kg/day in 2 divided doses until the day before surgery at which time they will stop CsA.
Study: NCT04967417
Drug: Pemetrexed, Carboplatin, Pembrolizumab
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Pemetrexed 500mg/m2~* Carboplatin AUC 5.0~* Pembrolizumab 200mg
Study: NCT04967417
Drug: Paclitaxel, Carboplatin, Pembrolizumab
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Paclitaxel 200mg/m2~* Caboplatin AUC 6.0~* Pembrolizumab 200mg
Study: NCT06695195
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 25 mg capsule twice daily
Study: NCT06732427
Drug: fospropofol Disodium for injection
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group L received slow intravenous sufentanyl 0. 1 ug / kg +fospropofol Disodium for injection 8mg / kg (completed within 60 seconds)
Study: NCT06732427
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group B received slow intravenous sufentanyl 0. 1 ug / kg +propofol 2mg / kg (completed within 60 seconds)
Study: NCT05064332
Drug: PF-06650833
Normalized name: PF-06650833
DrugBank: PF-06650833 (DB15143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg by mouth (PO) Once daily (QD) for 11 days
Study: NCT06731894
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT06731894
Drug: Dronabinol
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04560166
Drug: Naxitamab and GM-CSF in combination with irinotecan and temozolomide
Normalized name: recombinant human GM-CSF
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Irinotecan, solution for infusion (20 mg/mL)~* Temozolomide, capsules (5 mg, 20 mg and 100 mg)~* The humanized immunoglobulin isotype G (IgG1) monoclonal antibody (mAb) naxitamab, solution for infusion (4 mg/mL)~* Sargramostim (GM-CSF), lyophilized 250 µg single use vial (250 µg/vial)
Study: NCT04584034
Drug: Salbutamol
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol will be delivered using a Babyhaler spacer device. Ventolin will be used, brandname for Salbutamol sulfate. Ventolin contains the propellant HFA 134a.
Study: NCT01175525
Drug: CROMOLYN
Normalized name: Cromolyn
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn 200mg (dissolved in water) given 4 times a day
Study: NCT01175525
Drug: sugar pill
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pill Dissolved in water taken 4 times daily 30 minutes prior to meals
Study: NCT06509126
Drug: Panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered at the dosage of 6mg/kg as 60 minutes, or 90 minutes for doses over 1000 mg, intravenous infusion
Study: NCT06509126
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered at the dosage of 180 mg/m2 over 60 minutes intravenous infusion
Study: NCT06509126
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered at the dosage of 400 mg/m2 (bolus intravenous infusion) followed by continuous intravenous infusion over 46 hours at the dosage of 2400 mg/m2
Study: NCT06509126
Drug: L-folinic acid
Normalized name: L-Folinic acid
DrugBank: Levoleucovorin (DB11596)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered at the dosage of 200 mg/m2 over 120 minutes as intravenous infusion
Study: NCT06146491
Drug: Oral tablet and transdermal patch
Normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen Medicated Patch [Stratagraft]
DrugBank: Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen (DB16709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral combination of paracetamol -500mg and ibuprofen - 400mg will be given to group A and transdermal diclofenac patch - 200 mg will be given to group B.
Study: NCT05554068
Drug: Shingrix
Normalized name: Shingrix
DrugBank: Varicella zoster vaccine (recombinant) (DB13924)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shingrix vaccine will be given to all eligible patients at one to three year post allogeneic stem cell transplantation.
Study: NCT06490107
Drug: Durvalumab combined with S-1
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The treatment regimen for this study is as follows:~First 8 cycles of adjuvant therapy: Durvalumab 1500mg, (Day 1, IV, Q3W) and S-1 40mg/m2 (Day1-14, BID, Q3W), up to 8 cycles.~Maintenance therapy stage(6 cycles)：If the patients do not experience disease recurrence or intolerance after first 8 cycles of adjuvant therapy, then, Durvalumab 1500mg, (IV, Q4W), up to 6 cycles
Study: NCT05047055
Drug: Isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Phase for 2 months and Continuation phase for 2 months dose: 75 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for \>75 Kg) as a fixed-dose combination.
Study: NCT05047055
Drug: Rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Phase for 2 months and Continuation phase for 2 months dose: 150 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for \>75 Kg) as a fixed-dose combination.
Study: NCT05047055
Drug: Pyrazinamide
Normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Phase for 2 months only dose: 400 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for \>75 Kg) as a fixed-dose combination.
Study: NCT05047055
Drug: Ethambutol
Normalized name: Ethambutol
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Phase for 2 months and Continuation phase for 2 months dose: 275 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for \>75 Kg) as a fixed-dose combination.
Study: NCT05047055
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Phase for 2 months and Continuation phase for 2 months dose: 400 mg for 30 to 64 yrs AND 600 mg for 65 and above years of age.
Study: NCT05736341
Drug: Remimazolam besylate
Normalized name: Remimazolam Besylate
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After delivery, patients in this group receives 5mg of remimazolam to induce sedation during the remaining procedures of Cesarean section.
Study: NCT05736341
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After delivery, patients in this group receives 2mg of midazolam to induce sedation during the remaining procedures of Cesarean section.
Study: NCT04941599
Drug: 2-Hydroxybenzylamine
Normalized name: hydroxybenzopyridine
DrugBank: Benzylamine (DB02464)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-Hydroxybenzylamine (2-HOBA) 250 mg three tabs TID (po) for 6 weeks.
Study: NCT04245280
Drug: Ropivacaine 0.5% Injectable Solution
Normalized name: ROPivacaine 0.5% injectable solution
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ropivacaine 0.5% with epinephrine 2.5 mcg/ml
Study: NCT04245280
Drug: Saline Solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: normal saline solution (NaCl 0.9%)
Study: NCT03468556
Drug: SNP-610
Normalized name: SNP-ACTH (1-39)
DrugBank: SNP-ACTH (1-39) (DB18544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take 2 tablets once a day orally for 12 weeks
Study: NCT05514912
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05514912
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05514912
Drug: Infigratinib Phosphate
Normalized name: infigratinib phosphate
DrugBank: Infigratinib (DB11886)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05514912
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT06210438
Drug: SHR-A1921 + Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SHR-A1921 + Bevacizumab
Study: NCT05907382
Drug: JMKX003002 will be administered orally
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral once
Study: NCT05979909
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin (40 mg in 40 mL of sterile water) will be administered through a Foley catheter, which will be clamped for two hours.
Study: NCT04956302
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given SC
Study: NCT04956302
Drug: Daratumumab and Hyaluronidase-fihj
Normalized name: daratumumab-fihj / hyaluronidase-fihj Injection
DrugBank: Hyaluronidase (ovine) (DB00070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given SC
Study: NCT04956302
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO or IV
Study: NCT04956302
Drug: Panobinostat Lactate
Normalized name: panobinostat lactate
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT05525273
Drug: Oral dabrafenib and trametinib
Normalized name: Dabrafenib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Neoadjuvant or postoperative treatment of patients with verified BRAF mutated papillary craniopharyngioma
Study: NCT05579418
Drug: Evolocumab
Normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Evolocumab is an injection for management of dyslipidemia
Study: NCT05382312
Drug: Bedaquiline
Normalized name: Bedaquiline
DrugBank: Bedaquiline (DB08903)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bedaquiline will be administered.
Study: NCT05382312
Drug: Delamanid
Normalized name: delamanid
DrugBank: Delamanid (DB11637)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Delamanid will be administered.
Study: NCT05382312
Drug: RIFAFOUR e-275
Normalized name: E-EPA
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: RIFAFOUR e-275 will be administered.
Study: NCT05382312
Drug: BTZ-043
Normalized name: BTZ-043
DrugBank: BTZ-043 (DB17737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTZ-043 will be administered.
Study: NCT05264025
Drug: Fexofenadine
Normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablet
Study: NCT06244277
Drug: Suanzaoren Decoction and Huanglian Wendan Decoction
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Twice daily. Chinese herbal medicine includes: includes: 25 grams of Suanzaoren, 10 grams of chuanxiong, 30 grams of fushen, 10 grams of Polygala tenuifolia, 10 grams of Pinellia ternata, 12 grams of tangerine peel, 15 grams of Zhuru, 30 grams of forged keel, 30 grams of forged oyster,10 grams of aurantii fructus, 6 grams of coptis chinensis, 30 grams of Albizzia bark.Add or subtract Chinese herbal medicine according to the different clinical manifestations of each patient.
Study: NCT06244277
Drug: Zolpidem
Normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zolpidem 10Mg Tab 10mg tablet once daily
Study: NCT00002155
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002155
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00002155
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05610657
Drug: Mitapivat
Normalized name: Mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitapivat tablets
Study: NCT06732973
Drug: JS005
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: JS005：The drug was administered by a single subcutaneous injection
Study: NCT06732154
Drug: HRS-5632
Normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-5632 Injection
Study: NCT04511078
Drug: Panitumumab-IRDye800
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: single dose infusion of panitumumab-IRDye800CW
Study: NCT05766514
Drug: Cladribine
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be given 5 mg/m2 cladribine intravenously on days 1-5 of cycle 1 and on days 1-3 of cycles 2, 5, 6, 9, 10, 13, 14, 17 and 18.
Study: NCT05766514
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will be given 20 mg cytarabine subcutaneously twice daily on days 1-10 of cycles 1, 2, 5, 6, 9, 10, 13, 14, 17 and 18.
Study: NCT05766514
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be given 20 mg/m2 decitabine intravenously on days 1-5 of cycles 3, 4, 7, 8, 11, 12, 15 and 16
Study: NCT05766514
Drug: azacitidine or decitabine
Normalized name: Decitabine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will be given either 20 mg/m2 decitabine intravenously on days 1-5 of each cycle or 75 mg/m2 azacitidine intravenously or subcutaneously on days 1-7 of each cycle. The treating physician will determine which drug each subject will receive.
Study: NCT05766514
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subject will take 400 mg venetoclax orally once daily on days 1-21 of each cycle.
Study: NCT06029309
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will be administered Zanubrutinib orally (PO) via capsules daily during each 28-day cycle at the following dose levels:~* Phase 1 Dose Level 1: 320 mg~* Phase 1 Dose Level -1: 240 mg~* Phase 2: Recommended dose determined in Phase 1.
Study: NCT06029309
Drug: Tafasitamab
Normalized name: Tafasitamab
DrugBank: Tafasitamab (DB15044)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will be administered a 12 mg/kg dose of Tafasitamab intravenously (IV) during each 28-day cycle as follows:~* Early Induction - Cycle 1: Days 1, 4, 8, 15, and 22~* Early Induction - Cycles 2 and 3: Days 1, 8, 15 and 22~* Late Induction - Cycles 4 through 12: Days 1 and 15
Study: NCT05228899
Drug: Zofin
Normalized name: Zofin
DrugBank: Zofin (DB16519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mL of Zofin will be administered intravenously, containing 2-5 x 10\^11 particles/mL. Zofin will be diluted in 100 mL of sterile saline.
Study: NCT05852730
Drug: DPI-386 Nasal Gel
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will self-administer DPI-386 Nasal Gel
Study: NCT05852730
Drug: Other (e.g., promethazine, meclizine)
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will self-administer other medications as available.
Study: NCT05884281
Drug: Roflumilast
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 0.5 mg once daily for treatment period
Study: NCT05519579
Drug: Blinatumomab
Normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Blinatumomab 28ug/day continuous infusion for 4 weeks
Study: NCT05854225
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Thiotepa is an alkylating agent that is routinely used in solid tumors, but it is able to cross the blood-brain barrier into the center.
Study: NCT06580223
Drug: Aspirin 100mg
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin, enteric coating of tablets, oral administration
Study: NCT06580223
Drug: Rivaroxaban 10mg
Normalized name: RIVAROXABAN 10MG TAB
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban, tablets, oral administration.
Study: NCT05388500
Drug: Paclitaxel + Trastuzumab
Normalized name: Paclitaxel
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Regarding neoadjuvant treatment :~- 9 to 12 weeks of neoadjuvant treatment Trastuzumab IV (8mg/kg loading dose followed by 6 mg/kg maintenance dose) or SubCutaneous (SC) (600mg fixed dose) every 3 weeks + weekly Paclitaxel IV : 80 to 90 mg/m2~Regarding adjuvant treatment patients will receive one of the following anti-HER2 therapy following the current standard to complete 1 year of anti-HER2 therapy in total :~* in case of pCR : patient will receive trastuzumab~* in case of non pCR : patients will receive trastuzumab emtansine (T-DM1)
Study: NCT05388500
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Regarding neoadjuvant treatment :~- 9 to 12 weeks of neoadjuvant treatment Trastuzumab IV (8mg/kg loading dose followed by 6 mg/kg maintenance dose) or SC (600mg fixed dose) every 3 weeks~Regarding adjuvant treatment patients will receive one of the following anti-HER2 therapy following the current standard to complete 1 year of anti-HER2 therapy in total :~* in case of pCR : patient will receive trastuzumab~* in case of non pCR : patients will receive trastuzumab emtansine (T-DM1)
Study: NCT06525948
Drug: rhTPO
Normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhTPO
Study: NCT06525948
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclosporine A
Study: NCT05934812
Drug: Oxytocin nasal spray
Normalized name: oxytocin Nasal Spray
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24IU oxytocin liquid delivered with a pump-actuated nasal spray device, administered twice-daily
Study: NCT06239870
Drug: Envafolimab combined with chemoradiotherapy in the whole course of neoadjuvant therapy
Normalized name: varenicline
DrugBank: Envafolimab (DB15769)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each enrolled patient was given 2 cycles of induction chemotherapy combined with immunization, followed by immunization combined with chemoradiotherapy, and finally 2 cycles of consolidation chemotherapy combined immunization
Study: NCT06491472
Drug: Ivonescimab
Normalized name: Ivonescimab
DrugBank: Ivonescimab (DB18931)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg/kg,IV,d1,Q3W
Study: NCT06491472
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2, IV, d1/8, Q3W
Study: NCT06491472
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 125mg/m2, IV, d1/8, Q3W
Study: NCT05830162
Drug: Bioclavid (Amoxicillin and Clavulanic acid)
Normalized name: amoxicillin / clavulanate
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: We will evaluate how many women gets an infection and/or wound dehiscence after a second degree obstetric tear or episiotomy
Study: NCT06523530
Drug: Goserelin Acetate 3.6 mg inj, implant
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3.6 mg (1ml) administered subcutaneously once every month for 6 months (totally 6 injections)
Study: NCT05502705
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg until the end of the surgery